Status unknownNCT05480592Updated Mar 9, 2023

A Study of HS-10380 in Chinese Participants

A Phase 1 interventional study of HS-10380 and Placebo in Schizophrenia, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Phase: Phase 1
Study type: Interventional
Enrollment: 76
Allocation: Randomized
Ages: 18 Years to 45 Years
Sex: All

Study summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Read the detailed description

This is a phase I, randomized, double-blinded, placebo-controlled, both single ascending doses (SAD) study and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10380 in Chinese healthy subjects.

There will be four phases in SAD and MAD study: a 2-week screening phase, a 1-day baseline phase, a double-blind treatment phase, and a 1-week post-treatment (follow-up) phase.

Conditions studied

Schizophrenia

Browse trials for

Schizophrenia 3,471

Keywords

Schizophrenia
HS-10380

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's planned enrollment of 76 is close to the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 131 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 45 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Healthy subject aged from 18 to 45 years;
Subject has a Body Mass Index (BMI) between 18.5 and 26.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;
Voluntary subject who signs the informed consent form after understanding the purpose, content, process and possible risks of the trial;
Subject is able to communicate well with the investigator and comply with the lifestyle constraints specified in the protocol, and cooperate to complete the trial procedures.

Exclusion criteria

Exclusion Criteria:

Subject has history or presence of disease or dysfunction affecting the clinical trial, including but not limited to neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, musculoskeletal system, metabolic endocrine system, skin disease, blood system disease, immune system and tumor, etc.;
Subject has any surgical condition or condition that may significantly affect the absorption, distribution, metabolism, and excretion of the drug, or any surgical condition or condition that may pose a hazard to the subjects participating in the trial, such as gastrointestinal surgery (gastrectomy, Gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, peptic ulcer, history of gastrointestinal bleeding, etc.;
Subject has a history of significant drug allergies or known allergies to the components of the test drug;
Subject has history or presence of psychiatric disorders and cerebral dysfunction, or subjects at risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS) or at risk of suicide according to the investigator's clinical judgment, or has a history of self-harm;
Subject has a history of drug abuse within 1 year prior to screening, or has a positive urine drug result screen at screening;
Subject has history of alcohol abuse or a single consumption of more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 150 mL of wine) in the nearly one year prior to screening or a positive breath test for alcohol at screening;
Subject has smoked ≥5 cigarettes per day or consumed an average of ≥5 (200mL/cup) cups of coffee or tea per day in the 3 months before screening, or could not stop users during the study;
Subject has special requirements for food or is unwilling to accept a uniform diet or has difficulty swallowing;
Pregnant or breastfeeding women, or those who refuse to use effective contraception (eg, abstinence, IUD) throughout the study period and 6 months after the end of the study, or those who have a sperm or egg donation plan;
Subject has clinically significant abnormal comprehensive physical examination, vital signs, laboratory tests, and 12-lead electrocardiograms, which are judged by the investigator (eg: QTcF>450ms for men and >470ms for women, Friericia correction);
Subject with resting pulse rate \<55 bpm or >100 bpm; systolic blood pressure \<90mmHg or >140mmHg; diastolic blood pressure \<60mmHg or >90mmHg at screening;
Subject has detectable hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody at screening;
Subject with alanine aminotransferase (ALT), creatinine (Cr), blood urea nitrogen (BUN) exceeding the upper limit of normal or serum prolactin greater than 2 times the upper limit of normal at the time of screening;
Subject has donated blood or lost blood ≥ 400ml within 3 months before screening, or donated blood or lost blood ≥ 200ml within one month, or has a history of using blood products;
Subject with a history of surgery within 3 months prior to screening, or who have not recovered from surgery, or who have anticipated surgery plans during the trial;
Subject has taken any medication within 2 weeks (or 5 half-lives, whichever is longer) prior to screening or takes any medication throughout study, including prescription and over-the-counter medications, Chinese herbal medicines, and any drugs that inhibit or induce liver drug metabolizing enzymes (such as inducers and/or inhibitors of CYP3A4, CYP2D6 and CYP3A5);
Subject has participated in any clinical trial or took any clinical trial drugs within 3 months before screening;
Subject has dieted or received dietary therapy, or had significant changes in dietary habits within 30 days prior to screening;
Subject has a history of vaccination within 30 days prior to screening, or has a vaccination schedule throughout the study;
Subject with poor compliance or other problems which the investigator considers unsuitable for subject to participate.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Sequential assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 76 participants (estimated)

Study arms

Experimental
Single Ascending Dose (SAD)
Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.
Drug: HS-10380 · Drug: Placebo
Placebo comparator
Multiple Ascending Dose (MAD)
Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.
Drug: HS-10380 · Drug: Placebo

Interventions

DrugHS-10380
Administered orally as a tablet
DrugPlacebo
Administered orally as a tablet

What researchers measure

Primary outcomes

Number of Subjects Experiencing Adverse Events (AEs)
AE include adverse events (AEs) and serious adverse events (SAEs)
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Changes from baseline in laboratory tests
Laboratory tests include blood routine, urine routine, blood biochemistry, coagulation function, thyroid function and serum prolactin;
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Changes from baseline in vital signs
Vital signs include respiration, pulse, blood pressure, body temperature and SpO2
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in Electrocardiogram (ECG)
ECG parameters including heart rate, PR interval, RR interval and QTcF, etc.
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in weight (kg)
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in physical examination
Including general condition, heart, chest and abdomen, skin and mucous membranes, lymph node examination, etc.
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in Simpson-Angus Scale (SAS) score
The SAS is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in Abnormal Involuntary Movement Scale (AIMS) score
AIMS is a rating scale measuring involuntary movements known as tardive dyskinesia, that sometimes develop as a side effect of long-term treatment with antipsychotic medications. The AIMS score was calculated as the sum of questions 1 through 7 of the AIMS instrument, which includes assessments of involuntary movements in the face, lips, jaw, tongue, upper and lower extremities, and neck/shoulders/hips. Each item is rated on a five-point scale of severity from 0-4 with 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Total scores range from 0 to 28.
Time frame: Baseline to end of follow-up (a maximum of 20 days)
Change from baseline in Barnes Akathisia Rating Scale (BARS) score
BAS is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0-3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0-5. Total score ranges from 0 to 14 with a higher score indicating increased severity.
Time frame: Baseline to end of follow-up (a maximum of 20 days)

Secondary outcomes

Maximum plasma concentration (Cmax) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Time of the Maximum Concentration (Tmax) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Terminal rate constant (λz) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Elimination half-life (t1/2) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC0-∞) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Apparent clearance (CL/F) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Apparent volume of distribution (Vd/F) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Mean retention time (MRT) of single-dose HS-10380 administration
Time frame: Up to 120 hours post-dose
Maximum plasma concentration (Cmax) of first HS-10380 administration
Time frame: Up to 12 days
Time of the Maximum Concentration (Tmax) of first HS-10380 administration
Time frame: Up to 12 days
Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24) first HS-10380 administration
Time frame: Up to 24 hours
Maximum concentration at steady state (Css, max) of multiple-dose HS-10380 administration
Time frame: Up to 12 days
Time of the maximum concentration at steady state (Tss, max) of multiple-dose HS-10380 administration
Time frame: Up to 12 days
Minimum concentration at steady state (Css, min) of multiple-dose HS-10380 administration
Time frame: Up to 12 days
Area under the concentration-time curve at steady state (AUCss) of multiple-dose HS-10380 administration
Time frame: Up to 12 days
Accumulation ratio (RAC) after multiple doses
Time frame: Up to 12 days

Study locations

1 of 1 sites recruiting

Shanghai Mental Health Center
Shanghai, Shanghai 200030, China
- Yan Li, MD · Contact · liyan7721@163.com · 021-34773128
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05480592
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Responsible party: Sponsor
First posted: Jul 29, 2022
Start date: Aug 1, 2022
Primary completion: Jun 30, 2023 (estimated)
Completion: Jul 30, 2023 (estimated)
Last update: Mar 9, 2023

Study contacts

Huafang Li, MD

Contact

lhlh_5@163.com

021-34773128

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Schizophrenia→

Other studies from this sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Start the discussion